Printer Friendly

Browse Pembrolizumab topic

Articles

1-300 out of 600 article(s) nextnext page
Title Author Type Date Words
Agenus withdraws BLA for balstilimab, decides to discontinue BRAVA trial. Oct 22, 2021 260
I-Mab's Phase 2 trial of antitumor combination approved in China. Oct 18, 2021 229
BioXcel Therapeutics expands Phase 1b/2 trial of BXCL701. Oct 18, 2021 294
Tizona Initiates Phase 1b Expansion Study of TTX-080 in Advanced Refractory or Resistant Malignancies. Oct 15, 2021 402
First Patient Dosed in Phase 1 Clinical Trial Evaluating IO-108, a Novel Antagonist Antibody Targeting LILRB2, in Patients with Advanced Solid Tumors. Oct 15, 2021 457
NCI selects ImmunityBio's receptor agonist Anktiva -Keytruda combo for NSCLC. Oct 4, 2021 197
I-Mab reports multiple positive clinical updates of lemzoparlimab. Sep 30, 2021 261
Corvus recent rally due to AstraZeneca data, says Roth Capital. Sep 22, 2021 158
Cue Biopharma granted U.S. patents on CUE-101. Sep 21, 2021 258
TG Therapeutics announces combination data presentation at iwCLL. Sep 20, 2021 800
Aprea Therapeutics presents data from phase 1/2 trial of APR-246 in solid tumors. Sep 20, 2021 279
Silverback Therapeutics presents interim clinical results from SBT6050 trial. Sep 16, 2021 379
Athenex presents data from paclitaxel with pembrolizumab study. Sep 16, 2021 451
BioXcel presents results from ongoing Phase 2 trial of BXCL701-Keytruda combo. Sep 15, 2021 199
CG Oncology Forges Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Oncolytic Immunotherapy CG0070 in Combination with Opdivo in Metastatic Urothelial Cancer. Sep 9, 2021 269
PharmAbcine Receives HREC Clearance for Phase II Trial of Olinvacimab and Pembrolizumab in mTNBC. Sep 3, 2021 494
Comparison of PD-L1, EGFR, ALK, and ROS1 Status Between Surgical Samples and Cytological Samples in Non-Small Cell Lung Carcinoma. Ekin, Zübeyde; Nart, Deniz; Savas, Pinar; Veral, Ali Report Sep 1, 2021 6354
TG Therapeutics announces data presentations at upcoming XIX International. Aug 30, 2021 262
Cantargia reports first patient treated in pancreatic cancer study. Aug 26, 2021 259
Cantargia reports first patient treated in pancreatic cancer study. Aug 26, 2021 258
Cantargia reports first patient treated in pancreatic cancer study. Aug 26, 2021 257
Agenus announces results from Phase 2 study of balstilimab published. Aug 26, 2021 339
US FDA Clears Immune-Onc Therapeutics IND Application to Initiate First-In-Human Trial of IO-108, a Novel Antagonist Antibody Targeting LILRB2, in Patients with Advanced Solid Tumors. Aug 12, 2021 649
Immutep reports dosing of first patient for triple combination in INSIGHT-003. Aug 5, 2021 156
Exicure provides update on cavrotolimod trial. Aug 5, 2021 333
FDA expands pembrolizumab approval for cSCC. Worcester, Sharon Aug 1, 2021 378
Atreca presents initial clinical data from Phase 1b trial of ATRC-101. Jul 29, 2021 305
Rubius Therapeutics announces publication of RTX-240 preclinical data. Jul 15, 2021 204
Immutep expects to report further TACTI-002 data in 2021/early 2022. Jul 13, 2021 152
Galectin Therapeutics announces results from Phase 1b trial extension. Jul 9, 2021 374
Evaxion Biotech reports data from Phase 1/2a trials of EVX-01, EVX-02. Jul 8, 2021 498
XTX101 FDA APP ACCEPTED FOR SOLID TUMORS TREATMENT. Jul 1, 2021 427
Melanoma: An FP's guide to diagnosis and management: This review details the latest recommendations on dermoscopy and excision techniques, indications for sentinel lymph node biopsy, and Tx options. Wohltmann, Wendi; Servey, Jessica Clinical report Jul 1, 2021 4894
Akciger Kanserinde Tedavi Yanitinin Degerlendirilmesinde PET/BT: PET/CT in the Evaluation of Treatment Response in Lung Cancer. Ozmen, Ozlem Report Jul 1, 2021 6894
Immnoterapide Tedavi Yanitinin Degerlendirilmesinde PET/BT/The Role of PET/CT in the Evaluation of Tumour Response to Immunotherapy. Yildiz, Akin; Sahin, Zeliha; Forouz, Aria Report Jul 1, 2021 9833
Onkolojik Hastalarda Tedavi Yanitinin Degerlendirilmesinde PET/MR: PET/MRI in The Evaluation of Treatment Response in Oncological Patients. Aydos, Uguray; Atay, Lutfiye Ozlem Report Jul 1, 2021 10478
LATEST COMPANY NEWS. Jun 30, 2021 30696
Alpine Immune Sciences to Collaborate with US Merck on Immuno-Oncology Study to Evaluate ALPN-202 in Combination with Keytruda. Jun 30, 2021 244
Sellas Life Sciences reports data from ongoing Phase 1/2 study of GPS. Jun 30, 2021 568
Cantargia expands development of nadunolimab in additional cancers. Jun 29, 2021 232
Cantargia expands development of nadunolimab in additional cancers. Jun 29, 2021 231
Cantargia expands development of nadunolimab in additional cancers. Jun 29, 2021 233
BioInvent wins patent notice of allowance in China for BI-1206 for cancer. Jun 24, 2021 175
BioInvent wins patent notice of allowance in China for BI-1206 for cancer. Jun 24, 2021 174
Rubius Therapeutics doses 1st patient with RTX-240 in Keytruda combo. Jun 23, 2021 205
Jacobio Pharmaceuticals doses first patients in clinical trial of SHP2 inhibitor JAB-3312 in combination with Pembrolizumab and Binimetinib. Jun 18, 2021 162
Jacobio Pharmaceuticals doses first patients in clinical trial of SHP2 inhibitor JAB-3312 in combination with Pembrolizumab and Binimetinib. Jun 18, 2021 161
Xilio Therapeutics Gains FDA Acceptance of IND Application for XTX101 for the Treatment of Solid Tumors. Jun 18, 2021 344
LATEST COMPANY NEWS. Jun 15, 2021 29217
AIM ImmunoTech says Ampligen featured in medical journal as potential treatment for cancer patients infected with SARS-CoV-2. Jun 15, 2021 382
ImmVira announces completion of first dosing in phase II clinical trials of MVR-T3011 in US and China. Jun 14, 2021 197
ImmVira announces completion of first dosing in phase II clinical trials of MVR-T3011 in US and China. Jun 14, 2021 198
ALX Oncology announces updates on ASPEN-03, ASPEN-04 studies. Jun 14, 2021 190
LATEST COMPANY NEWS. Jun 8, 2021 28094
Cantargia preparing to start clinical trial of nadunolimab and FOLFIRINOX. Jun 8, 2021 178
Cantargia preparing to start clinical trial of nadunolimab and FOLFIRINOX. Jun 8, 2021 179
Cantargia preparing to start clinical trial of nadunolimab and FOLFIRINOX. Jun 8, 2021 177
iTeos Therapeutics announces new phase 1/2a data on inupadenant. Jun 4, 2021 401
Alkermes announces new data from ARTISTRY program for nemvaleukin alfa. Jun 4, 2021 199
Achilles Therapeutics presents phase I/IIa clinical trial design of CHIRON. Jun 4, 2021 190
Iovance Biotherapeutics announces data for lifileucel w/ pembrolizumab. Jun 4, 2021 219
Agenus to present on balstilimab, provide clinical update on AGEN2373. Jun 4, 2021 332
Merck says Keytruda reduced risk of disease recurrence in Phase 3 trial. Jun 3, 2021 182
QBiotics doses first patient in Phase Ib/IIa clinical trial of tigilanol tiglate in combination with KEYTRUDA. Jun 3, 2021 207
QBiotics doses first patient in Phase Ib/IIa clinical trial of tigilanol tiglate in combination with KEYTRUDA. Jun 3, 2021 208
Checkpoint-inhibitor skin effects more common in women. Otto, M. Alexander Jun 1, 2021 566
Adverse reactions to immunotherapy can appear after a year. Otto, M. Alexander Jun 1, 2021 1087
LATEST COMPANY NEWS. Jun 1, 2021 27308
Population-level changes in outcomes and Medicare cost following the introduction of new cancer therapies. Youn, Bora; Wilson, Ira B.; Mor, Vincent; Trikalinos, Nikolaos A.; Dahabreh, Issa J. Report Jun 1, 2021 6247
Pan-Cancer Biomarkers: Changing the Landscape of Molecular Testing. Yao, Jinjuan; Arcila, Maria E.; Ladanyi, Marc; Hechtman, Jaclyn F. Report Jun 1, 2021 5789
Sellas Life Sciences announces notice of allowance for patent covering GPS. May 27, 2021 160
Transgene and BioInvent Receive IND Approval from the US FDA for BT-001, a Novel Oncolytic Virus for the Treatment of Solid Tumors. May 27, 2021 718
GNS Healthcare plans to develop Gemini - The in silico Patient for Prostate Cancer. May 26, 2021 164
GNS Healthcare plans to develop Gemini - The in silico Patient for Prostate Cancer. May 26, 2021 163
LATEST COMPANY NEWS. May 25, 2021 27529
Oncolytics's combination therapy in pancreatic cancer shows proof-of-concept. May 20, 2021 278
Sensei Biotherapeutics announces new clinical data from combo trial of SNS-301. May 19, 2021 262
Iovance announces additional clinical data for lifileucel. May 19, 2021 258
Advaxis announces update from ADXS-503 study. May 19, 2021 412
Galectin Therapeutics reports Q1 EPS (11c), one est. (17c). Financial report May 17, 2021 287
IN BRIEF: Merck & Co breast cancer treatment sees positive results. May 13, 2021 162
LATEST COMPANY NEWS. May 10, 2021 26917
Genprex in-licenses additional gene therapy technologies to treat non-small cell lung cancer. May 7, 2021 276
Immutep on track to start TACTI-003 study in mid-2021. May 7, 2021 229
Iovance Biotherapeutics sees lifileucel BLA submission during 2021. May 7, 2021 215
Nektar reports Q1 EPS (68c), consensus (72c). Financial report May 6, 2021 213
Checkmate Pharmaceuticals reports initiation of Phase 2 CMP-001 trial. May 4, 2021 230
Pathologic Manifestations of Gastrointestinal and Hepatobiliary Injury in Immune Checkpoint Inhibitor Therapy. Patil, Pallavi A.; Zhang, Xuchen Report May 1, 2021 8342
Merkel cell carcinoma of the gluteal region: A rare case report and literature review. Corapli, Mahmut; Pehlivanoglu, Burcin; Bulut, Haci Taner; Alakus, Huseyin; Akdeniz, Nadiye Clinical report Apr 30, 2021 1713
GlaxoSmithKline and Merck discontinue trials involving feladilimab. Apr 15, 2021 155
TILT Biotherapeutics, MSD to Collaborate on Clinical Trial of Adenoviral Cancer Immunotherapeutic TILT-123 in Combination with Keytruda for Ovarian Cancer. Apr 15, 2021 365
Genprex presents positive preclinical data for lung cancer drug REQORSA at American Association for Cancer Research meeting. Apr 13, 2021 529
Genprex targets non-small cell lung cancer and diabetes via gene therapy. Apr 13, 2021 780
iTeos announces preliminary data from ongoing Phase 1/2a trial of EOS-448. Apr 11, 2021 407
Advaxis presents translational biomarker data from ADXS-503 Phase 1/2 trial. Apr 11, 2021 349
Checkmate presents new clinical trial translational data with Vidutolimod. Apr 11, 2021 190
Alkermes signs clinical trial collaboration and supply agreement with MSD. Apr 8, 2021 294
Alkermes signs clinical trial collaboration and supply agreement with MSD. Apr 8, 2021 293
Genprex targets non-small cell lung cancer and diabetes via gene therapy. Apr 7, 2021 773
The significance of mismatch repair deficiency in endometrial cancer. Rossi, Emma Apr 1, 2021 1131
Genprex to present preclinical data for lung cancer drug REQORSA at American Association for Cancer Research meeting. Mar 31, 2021 415
LATEST COMPANY NEWS. Mar 30, 2021 29777
Adagene announces clinical advancement for ADG116. Mar 29, 2021 403
Sensei Biotherapeutics announces 2021, 2022 anticipated milestones. Mar 25, 2021 152
Corvus Pharmaceuticals reports Q4 EPS 92c, consensus (32c). Financial report Mar 25, 2021 173
LATEST COMPANY NEWS. Mar 23, 2021 30362
Immutep enters second collaboration with Merck for Phase IIB trial in HNSCC. Mar 16, 2021 198
U.S. recruits sought for vaccine trial. Mar 15, 2021 948
Transgene, BioInvent Enroll First Patient in Phase I/IIa Trial of Novel Oncolytic Virus BT-001 in Solid Tumors. Mar 2, 2021 846
Recent advancement on PD-L1 expression quantification: the radiologist perspective on CT-guided FNAC. Casale, Silvia; Bortolotto, Chandra; Stella, Giulia Maria; Filippi, Andrea Riccardo; Gitto, Salvator Report Mar 1, 2021 3869
Expert perspectives on studies that analyze HPV vaccination and cervical cancer rates, combination immunotherapy for recurrent endometrial cancer, and talcum powder's role in ovarian cancer risk. Dioun, Shayan; Wright, Jason D. Mar 1, 2021 2815
PD-L1 testing and immunotherapy selection - early laboratory experience and its potential role in head and neck cancer management. Bancu, Andrei; Cowan, Richard; Chaturvedi, Anshuman Mar 1, 2021 2047
4D pharma Inks Clinical Trial Collaboration and Supply Agreement with Merck KGaA and Pfizer to Evaluate MRx0518 in Combination with BAVENCIO for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma. Feb 9, 2021 950
ADC Therapeutics Completes Enrollment in Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine in Relapsed or Refractory Hodgkin Lymphoma. Feb 5, 2021 594
4D Pharma updates on status of oncology program. Feb 4, 2021 820
Upper Crust owner SSP lifted by broker upgrade. Feb 4, 2021 2519
Proactive news headlines:AaGalantas Gold Corporation,Aa4D Pharma PLC,AaOriole Resources PLC, Argo Blockchain PLC ... Feb 4, 2021 2243
FTSE 100 closes in the red mid-week as investor sentiment wanes. Feb 4, 2021 4819
Highlight Therapeutics looks to boost the power and reach of immuno-oncology drugs. Feb 2, 2021 605
Highlight Therapeutics: on a mission to extend benefits of immuno-oncology drugs. Jan 30, 2021 882
TOP NEWS: Glaxo And Merck KGaA Discontinue Bintrafusp Alfa Trial. Jan 20, 2021 246
LONDON MARKET CLOSE: Stocks Rise As Biden Assumes US Presidency. Jan 20, 2021 1459
Transgene, BioInvent Receive Approval from ANSM to Proceed with Phase I/IIa Trial of Anti-CTLA4-armed Oncolytic Virus BT-001 in Solid Tumors. Jan 19, 2021 836
BioInvent and Cancer Research UK revise clinical development agreement for BI-1206. Jan 11, 2021 224
BioInvent and Cancer Research UK revise clinical development agreement for BI-1206. Jan 11, 2021 223
BioInvent and Cancer Research UK revise clinical development agreement for BI-1206. Jan 11, 2021 219
Evaluating Mismatch Repair/Microsatellite Instability Status Using Cytology Effusion Specimens to Determine Eligibility for Immunotherapy. Jacobi, Elizabeth M.; Landon, Gene; Broaddus, Russell R.; Roy-Chowdhuri, Sinchita Report Jan 1, 2021 5776
Vaccine regimen boosts immune responses in melanoma study. Rans, Caleb Clinical report Jan 1, 2021 429
Transgene and BioInvent Receive CTA Approval for Phase 1/2a Trial of Oncolytic Virus BT-001 in Solid Tumors. Dec 22, 2020 561
CG Oncology Closes USD 47m Series D Financing. Dec 11, 2020 198
Targovax ONCOS-102 trial in anti-PD1 refractory melanoma patients demonstrates best objective responses. Dec 2, 2020 217
Targovax ONCOS-102 trial in anti-PD1 refractory melanoma patients demonstrates best objective responses. Dec 2, 2020 216
Targovax ONCOS-102 trial in anti-PD1 refractory melanoma patients demonstrates best objective responses. Dec 2, 2020 212
What happened to melanoma care during spring lockdown? Jancin, Bruce Dec 1, 2020 1476
Real-world survival data with checkpoint inhibitors: Studies show outcomes may differ from clinical trial results. Fuerst, Mark L. Clinical report Dec 1, 2020 1176
City of Hope COVID-19 Investigational Vaccine Produces Strong Immunity in Preclinical Research. Dec 1, 2020 668
First Patient Dosed in Phase 1 Open-Label Clinical Trial of SNX281 for Advanced Solid Tumors or Lymphoma. Nov 24, 2020 680
Nurse: I've been failed over cancer treatment. ZOE CHAMBERLAIN News Reporter zoe.chamberlain@reachplc.com Nov 24, 2020 482
Agilent awarded expanded FDA approval for PD-L1 IHC 22C3 pharmDx in triple-negative breast cancer. Nov 16, 2020 233
Agilent awarded expanded FDA approval for PD-L1 IHC 22C3 pharmDx in triple-negative breast cancer. Nov 16, 2020 237
4D pharma unveils positive clinical data from immuno-oncology candidate trials. Nov 10, 2020 582
Proactive news headlines:AaIQ-AI,Aa88 Energy,AaOne Media IP Group,AaZaim Credit Systems ... Nov 10, 2020 3324
First Patient Dosed with Camidanlumab Tesirine in Combination with Pembrolizumab in Ongoing Phase 1b Clinical Trial in Selected Solid Tumors. Nov 4, 2020 614
Melanoma treatment may offer hope after immunotherapy. Davenport, Liam Nov 1, 2020 729
Multivariable Analysis of 169 Cases of Advanced Cutaneous Melanoma to Evaluate Antibiotic Exposure as Predictor of Survival to Anti-PD-1 Based Immunotherapies. Swami, Umang; Chennamadhavuni, Adithya; Borcherding, Nicholas; Bossler, Aaron D.; Mott, Sarah L.; Ga Nov 1, 2020 4591
EXPOSURE ASSESSMENT OF PHARMACEUTICAL POWDERS BASED ON AN ENVIRONMENTAL MONITORING METHOD: A PILOT STUDY. Yildirim, Fatma Demircan; Ekmekci, Ismail Report Nov 1, 2020 7468
AIM ImmunoTech CEO Thomas Equels named Entrepreneur of the Year by BioFlorida. Oct 31, 2020 739
LONDON BRIEFING: Shell Commits To Rebuilding Payout With New Cash Plan. Oct 29, 2020 1853
Advaxis announces results from combination arm of Phase 1/2 ADXS-503 study. Oct 26, 2020 419
Mirati reports preliminary results from mutant KRAS selective inhibitor programs. Financial report Oct 25, 2020 438
Kitov Pharmaceuticals presents new mechanism of action data for NT219. Oct 16, 2020 251
Checkmate Pharmaceuticals announces data presentations for CMP-001. Oct 15, 2020 1268
Checkmate announces early release of data to be presented on CMP-001. Oct 15, 2020 166
Linnaeus Therapeutics doses first patient in phase 1/2 adaptive-design clinical trial of LNS8801, in combination with KEYTRUDA. Oct 14, 2020 177
Linnaeus Therapeutics doses first patient in phase 1/2 adaptive-design clinical trial of LNS8801, in combination with KEYTRUDA. Oct 14, 2020 181
AIM ImmunoTech is developing immuno-therapeutics to treat multiple types of cancers and fighting coronavirus too. Oct 14, 2020 1391
FIRST PATIENTS DOSED WITH INT230-6 AND KEYTRUDA. Clinical report Oct 1, 2020 832
Building a Canadian Translational Bladder Cancer Research Network. Koti, Madhuri; Berman, David M.; Siemens, D. Robert; Lange, Dirk; Wang, Edwin; Toren, Paul; Eigl, Be Report Oct 1, 2020 7315
Calithera Biosciences initiates KEAPSAKE Phase 2 trial of telaglenastat. Sep 24, 2020 246
ALX Oncology, Merck to collaborate on Phase 2 immuno-oncology studies of ALX148. Sep 22, 2020 230
Intensity Therapeutics Doses First Patient with Combination of INT230-6 and Bristol Myers Squibb's Yervoy in a Phase 2 Study. Clinical report Sep 18, 2020 545
Alkermes presents ARTISTRY-1 data, expands monotherapy melanoma cohort. Sep 18, 2020 189
Exicure to present interim cavrotolimod data at virtual KOL event. Sep 16, 2020 479
New drug treatment for Scottish grandfather with 'super rare' brain tumours; A grandfather believed to be the only person in the UK to suffer from a super rare form of brain tumour has received new treatment to shrink them. Sarah Ward and Helen McArdle Sep 16, 2020 528
Treadwell Initiates Patient Dosing in TWT-101, a Phase 1/2 Study of HPK1 Inhibitor, CFI-402411, in Patients with Solid Tumors. Sep 3, 2020 332
Genprex appoints Dr William Gannon as the company's vice president of Regulatory Affairs. Sep 3, 2020 520
The Current Strategies for Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer: The Place of Immunotherapy in Future. Ercelep, Ozlem Sep 1, 2020 2358
Immune-Related lncRNA Risk Signatures Predict Survival of IDH Wild-Type and MGMT Promoter Unmethylated Glioblastoma. Li, Xiaozhi; Meng, Yutong Report Aug 31, 2020 3007
Development of an Immune-Related Risk Signature in Patients with Bladder Urothelial Carcinoma. Jiang, Yaofei; Wang, Yibing; Li, Cong; Zou, Zhenhong; Liang, Bo Report Aug 31, 2020 4859
Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors. Xiao, Yan; Zeng, Lin; Shen, Qinglin; Zhou, Zhiyong; Mao, Zhifang; Wang, Qin; Zhang, Xiquan; Li, Ying Aug 31, 2020 6356
Profound Functional Suppression of Tumor-Infiltrating T-Cells in Ovarian Cancer Patients Can Be Reversed Using PD-1-Blocking Antibodies or DARPin[R] Proteins. Foord, Emelie; Klynning, Charlotte; Schoutrop, Esther; Forster, Judith M.; Krieg, Jennifer; Mortberg Aug 31, 2020 7844
Ethyl Acetate Fraction from Hedyotis diffusa plus Scutellaria barbata Exerts Anti-Breast Cancer Effect via miR-200c-PDE7B/PD-L1-AKT/MAPK Axis. Yang, Yue; Fang, Ting; Cao, Yi-Lan; Lv, Ya-Xin; Chang, Qing-Qi; Zhan, Dan-Dan Aug 31, 2020 4660
Euglycemic Ketoacidosis in a Patient with Metastatic Non-Small-Cell Lung Adenocarcinoma and Concomitant Pulmonary Embolism. O'Neill, Robert Sean; Tyack, Lauren; Freeman, Mary; Hussein, Hussein Soudy Aug 31, 2020 1927
Inflammatory Myeloradiculitis Secondary to Pembrolizumab: A Case Report and Literature Review. Vickers, M.L.; Seidl, B.; Bigby, K.; Chern, B.; Eriksson, L.; Hartnett, G.; Gericke, C.; Chew, R. Aug 31, 2020 3057
Uterine Carcinosarcoma: A Case Report and Literature Review. Kord, Ali; Rabiee, Behnam; Younes, Ismail Elbaz; Xie, Karen L. Aug 31, 2020 3589
Relationship between SP142 PD-L1 Expression and [sup.18]F-FDG Uptake in Non-Small-Cell Lung Cancer. Zhao, Long; Liu, Jinjun; Shi, Jingyun; Wang, Huoqiang Aug 31, 2020 7254
AIM ImmunoTech reports swelling cash on hand, coronavirus/cancer advancement of Ampligen in 2Q update. Aug 18, 2020 786
BioXcel expects data from Phase 1b/2 study of BXCL701 later this year. Aug 14, 2020 244
Aduro Biotech reports Q2 EPS (21c), consensus (19c). Financial report Aug 3, 2020 218
Shorts. Klotter, Jule Aug 1, 2020 1918
On the cover Repurposed Drugs for Cancer. Schor, Jacob Cover story Aug 1, 2020 4888
Optimizing management of advanced urothelial carcinoma: A review of emerging therapies and biomarker-driven patient selection. Black, Peter C.; Alimohamed, Nimira S.; Berman, David; Blais, Normand; Eigl, Bernhard; Karakiewicz, Aug 1, 2020 7220
Cancer Immunotherapy in Solid Organ Transplanted Patients/Solid-Organ Transplantasyonu Olan Hastalarda Kanser Immunoterapisi. Abdi, Ali; Oktelik, Fatma Betul; Bicer, Mehtap Dogruel; Gurol, Ali Osman Aug 1, 2020 5719
Response to Ipilimumab/Nivolumab Rechallenge and BRAF Inhibitor/MEK Inhibitor Rechallenge in a Patient with Advanced Metastatic Melanoma Previously Treated with BRAF Targeted Therapy and Immunotherapy. Myrdal, Caitlyn N.; Sundararajan, Srinath Jul 31, 2020 3179
Tumor Primary Location May Affect Metastasis Pattern for Patients with Stage IV NSCLC: A Population-Based Study. Shan, Qinge; Li, Zhenxiang; Lin, Jiamao; Guo, Jun; Han, Xiao; Song, Xinyu; Wang, Haiyong; Wang, Zheh Report Jul 31, 2020 4865
Predictive and Prognostic Role of PD-L1 in Urothelial Carcinoma Patients with Anti-PD-1/PD-L1 Therapy: A Systematic Review and Meta-Analysis. Liu, Haoran; Ye, Tao; Yang, Xiaoqi; Lv, Peng; Wu, Xiaoliang; Zhou, Hui; Lu, Hongyan; Tang, Kun; Ye, Jul 31, 2020 14681
The Terrible Triad of Checkpoint Inhibition: A Case Report of Myasthenia Gravis, Myocarditis, and Myositis Induced by Cemiplimab in a Patient with Metastatic Cutaneous Squamous Cell Carcinoma. Jeyakumar, Nikeshan; Etchegaray, Mikel; Henry, Jason; Lelenwa, Laura; Zhao, Bihong; Segura, Ana; Buj Jul 31, 2020 2738
First Patient Dosed in the Phase Ib Study of MDM2-p53 Inhibitor APG-115 as Single Agent and in Combinations for the Treatment of Hematologic Malignancies in China. Jul 24, 2020 799
Lancet publishes data on MacroGenics' Margetuximab in gastric cancer. Jul 9, 2020 165
Ascentage Pharma announces clinical collaboration with MSD. Jul 7, 2020 151
Ascentage Pharma announces clinical collaboration with MSD. Jul 7, 2020 155
US Food and Drug Administration Has Lifted Partial Clinical Hold on Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine. Jul 7, 2020 568
4D Pharma Starts Treatment Of Patients In Phase 2 Of MRx0518 Trial. Jul 6, 2020 322
The expanding role of biomarker testing in non-small cell lung cancer. Vennapusa, Bharathi Jul 1, 2020 1948
Molecular Targeted Cancer Therapies and the Kidney. Aksu, Ozge Bas; Sadioglu, Rezzan Eren; Sengul, Sule Jul 1, 2020 6275
Hypocalcemia with Immune Checkpoint Inhibitors: The Disparity among Various Reports. Nalluru, Swarna Sri; Piranavan, Paramarajan; Ning, Ying; Ackula, Haritha; Siddiqui, Ahmad D.; Trived Jun 30, 2020 3014
Identification of PDLl-Related Biomarkers to Select Lung Adenocarcinoma Patients for PD1/PDL1 Inhibitors. Wu, Yanping; Lin, Lianjun; Liu, Xinmin Jun 30, 2020 5697
Advanced Renal Pelvic Carcinoma Revealed after Treatment of a Staghorn Calculus by Endoscopic Combined Intrarenal Surgery. Tsuboi, Ichiro; Maruyama, Yuki; Araki, Motoo; Ando, Nobuyoshi; Nishiyama, Yasuhiro; Arata, Ryoji; On Jun 30, 2020 1679
Glucocorticoid Receptor Expression Predicts Good Outcome in response to Taxane-Free, Anthracycline-Based Therapy in Triple Negative Breast Cancer. Elkashif, Ahmed; Bingham, Victoria; Haddock, Paula; Humphries, Matthew P.; McQuaid, Stephen; Mullan, Jun 30, 2020 5719
Defining the Ideal Patient with Hepatocellular Carcinoma for Second-Line Treatment. Roviello, Giandomenico; Casadei-Gardini, Andrea; Nobili, Stefania; Mini, Enrico; Fancelli, Sara Jun 30, 2020 2525
Profiles of PD-1, PD-L1, PD-L2 in Gastric Cancer and Their Relation with Mutation, Immune Infiltration, and Survival. Liu, Jingwei; Li, Hao; Sun, Liping; Yuan, Yuan; Xing, Chengzhong Jun 30, 2020 5089
Profiles of Immune Infiltration and Prognostic Immunoscore in Lung Adenocarcinoma. Li, Yanyan; Tao, Liping; Cai, Weiyang Jun 30, 2020 9865
First Patient Dosed in Phase 1b/2a Study of NT-I7 (efineptakin alfa) and KEYTRUDA (pembrolizumab) in Patients with Relapsed/Refractory Advanced Solid Tumors. Jun 25, 2020 345
Seattle Genetics Initiates Phase 1 Clinical Trials for Two Novel Antibody-Based Drug Candidates. Jun 22, 2020 523
Revolution Medicines doses first patient in study of RMC-4630, PD-1 inhibitor. Jun 22, 2020 310
IsoRay, University of Cincinnati Physicians Company sign research agreement. Jun 17, 2020 258
Genprex ramps up production of active agent for its lung cancer drug Oncoprex. Jun 17, 2020 335
OncoSec to expand KEYNOTE-890 study with combination with TAVO and KEYTRUDA. Jun 9, 2020 175
The Cancer Immunotherapy Biomarker Testing Landscape. Walk, Eric E.; Yohe, Sophia L.; Beckman, Amy; Schade, Andrew; Zutter, Mary M.; Pfeifer, John; Berry, Jun 1, 2020 16518
MERKEL CELL PROGRESS: Management undergoes a revolution. Jancin, Bruce Jun 1, 2020 1418
Pulmonary Complications Secondary to Immune Checkpoint Inhibitors. Ahmad Hasan Albitar, Hasan; Duma, Narjust; Leventakos, Konstantinos; De Moraes, Alice Gallo May 31, 2020 3226
An Episode of Pseudothrombocytopenia during Pembrolizumab Therapy in NSCLC Patient. Krukowska, Kinga; Kieszko, Robert; Kurek, Katarzyna; Chmielewska, Izabela; Krawczyk, Pawel; Milanows May 31, 2020 2517
Immunocheckpoint Inhibitor- (Nivolumab-) Associated Hypereosinophilia in Non-Small-Cell Lung Carcinoma. Singh, Navdeep; Singh Lubana, Sandeep; Constantinou, George; Leaf, Andrea N. May 31, 2020 3548
Long-Term Follow-up of a Randomized Study of Oral Etoposide versus Viscum album Fermentatum Pini as Maintenance Therapy in Osteosarcoma Patients in Complete Surgical Remission after Second Relapse. Longhi, Alessandra; Cesari, Marilena; Serra, Massimo; Mariani, Erminia Clinical report May 31, 2020 5374
The Efficacy and Safety of PD-1/PD-L1 Inhibitors in Combination with Conventional Therapies for Advanced Solid Tumors: A Meta-Analysis. Nie, Run-Cong; Zhao, Chong-Bang; Xia, Xiao-Wei; Luo, Ying-Shan; Wu, Ting; Zhou, Zhi-Wei; Yuan, Shu-Q Report May 31, 2020 6865
Immutep announces data from Phase II TACTI-002 study. May 31, 2020 188
Autolus Therapeutics presents additional data on AUTO3 in DLBCL. May 29, 2020 230
BioLineRx's ongoing COMBAT trial featured in peer-reviewed journal. May 27, 2020 181
AGREEMENT EXPANDS GENPREX ONCOLOGY FRANCHISE. May 27, 2020 579
THE TESTS AND TREATMENTS IN THE PIPELINE. May 26, 2020 334
TESTS AND TREATMENTS THAT ARE IN THE PIPELINE; HEALTHBE your best Edited by AMY PACKER yourhealth@mirror.co.uk E. AMY PACKER May 26, 2020 336
Kitov announces FDA acceptance of IND application for Phase 1/2 trial of NT219. May 22, 2020 319
Kitov Pharmaceuticals to present preclinical data on NT219. May 19, 2020 197
Oncimmune's study data to be featured at prestigious cancer research conference. Conference news May 15, 2020 334
Immupharma lifted by US university study. Clinical report May 15, 2020 3351
Proactive news headlines: ImmuPharma, Tiziana Life Sciences, Echo Energy, Bango ... May 15, 2020 3297
BioXcel Therapeutics expects data from Phase 1b/2 study of BXCL701 in Q4. May 12, 2020 175
4D Pharma Completes First Part Of Clinical Trial For Cancer Treatment. May 11, 2020 244
Genprex shares soar as it strikes new worldwide license deal with MD Anderson for Oncoprex. May 6, 2020 493
Genprex CEO Rodney Varner says company's near-term future 'could be transformational'. May 5, 2020 592
Aduro Biotech reports Q1 EPS (9c), consensus (13c). Financial report May 4, 2020 184
FDA APPROVES AGILENT PD-L1 CDX ON DAKO OMNIS. May 1, 2020 317
NCCN panel: Defer nonurgent skin cancer care. Otto, M. Alexander May 1, 2020 613
Single Solitary Fibrous Tumor Brain Metastasis in a Patient with Simultaneous Adenocarcinoma of the Lung: Case Report and Review of the Literature. Kaya, Erin A.; Carlson, Jonathan D.; Thomas, Cheddhi J.; Wagner, Aaron E.; Fairbanks, Robert K.; Lam Apr 30, 2020 3903
Expression and Significance of Immune Checkpoints in Clear Cell Carcinoma of the Uterine Cervix. Zong, Liju; Zhang, Qianqian; Zhou, Yuncan; Kong, Yujia; Yu, Shuangni; Chen, Jie; Zhang, Youzhong; Xi Apr 30, 2020 4670
Critical Care Admission of an HIV Patient with Diabetic Ketoacidosis Secondary to Pembrolizumab. Cuenca, John A.; Laserna, Andres; Reyes, Maria P.; Nates, Joseph L.; Botz, Gregory H. Apr 30, 2020 2059
A Case Report with Severe Thrombocytopenia Induced by Axitinib. Koksal, Ulkuhan I.; Goffin, Janeiro Valle; Lewis, Brian; Sartor, Oliver A.; Belyaeva, Elizaveta; Soc Apr 30, 2020 2568
Leptomeningeal Disease as a Rare Complication of Primary Penile Urethral Cancer. Chen, Nan; Wheeler, Thomas; Coburn, Michael; Yen, Aihua Edward Apr 30, 2020 1588
Epidemiology of Microsatellite Instability High (MSI-H) and Deficient Mismatch Repair (dMMR) in Solid Tumors: A Structured Literature Review. Lorenzi, Maria; Amonkar, Mayur; Zhang, Jacky; Mehta, Shivani; Liaw, Kai-Li Apr 30, 2020 9345
BioXcel Therapeutics initiates Phase 2 study of BXCL701. Report Apr 28, 2020 255
Verastem Oncology to Present Clinical Data from Investigator-initiated RAF/MEK and FAK Combination Study in KRAS Mutant Solid Tumors. Apr 15, 2020 865
Genprex gene therapy candidate Oncoprex fast-tracking for non-small cell lung cancer treatment. Apr 8, 2020 1507
Immunomedics obtains Fast Track designation for sacituzumab govitecan. Apr 7, 2020 233
Seattle Genetics: potential accelerated approval pathway in U.S. for PADCEV. Apr 2, 2020 195
Intensity Therapeutics Reports Safety Results from First Cohort of the KEYNOTE A10 Combination Clinical Trial of INT230-6 and Keytruda. Clinical report Apr 2, 2020 642
Membranoproliferative Glomerulonephritis Associated with Nivolumab Therapy. Cruz-Whitley, Jessica; Giehl, Nolan; Jen, Kuang-Yu; Young, Brian Mar 31, 2020 2208
Cost-Effectiveness Analysis of Biomarker-Guided Treatment for Metastatic Gastric Cancer in the Second-Line Setting. Lauren, Brianna; Ostvar, Sassan; Silver, Elisabeth; Ingram, Myles; Oh, Aaron; Kumble, Lindsay; Laszk Mar 31, 2020 6241
Network Pharmacology Study on the Pharmacological Mechanism of Cinobufotalin Injection against Lung Cancer. Mao, Yun; Peng, Xi; Xue, Peng; Lu, Dianrong; Li, Linlu; Zhu, Shijie Report Mar 31, 2020 6634
Sellas Life Sciences reports FY19 EPS ($10.92), two est. ($9.70). Financial report Mar 13, 2020 167
BioXcel Therapeutics currently enrolling expansion cohort in BXCL701 study. Report Mar 9, 2020 206
Meet this year's 8 and good; international women's day: in praise of irish girl power; Honouring females in media, arts & politics. SYLVIA POWNALL and EMMA MCMENAMY Mar 8, 2020 1109
Targovax concludes enrollment of 21 patients with Anti-PD1 refractory melanoma under ONCOS-102 trial. Mar 3, 2020 226
Targovax concludes enrollment of 21 patients with Anti-PD1 refractory melanoma under ONCOS-102 trial. Mar 3, 2020 230
A Case Report with Severe Thrombocytopenia Induced by Axitinib. Koksal, Ulkuhan I.; Goffin, Janeiro; Lewis, Brian; Sartor, Oliver A.; Belyaeva, Elizaveta; Socola, F Mar 1, 2020 2552
Pembrolizumab-Induced Mobitz Type 2 Second-Degree Atrioventricular Block. Khan, Alisha; Riaz, Sana; Carhart, Robert, Jr. Mar 1, 2020 1999
Detection of Fusion Genes Using a Targeted RNA Sequencing Panel in Gastrointestinal and Rare Cancers. Lee, Su Jin; Hong, Jung Yong; Kim, Kyung; Kim, Kyoung-Mee; Kang, So Young; Lee, Taeyang; Kim, Seung Mar 1, 2020 4701
Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions. Kreidieh, Malek; Mukherji, Deborah; Temraz, Sally; Shamseddine, Ali Mar 1, 2020 20117
US Merck Receives Complete Response Letter from the US FDA for Supplemental Biologics License Applications for Keytruda Six-Week Dosing Schedule. Feb 24, 2020 257
US Merck Receives Complete Response Letter from the US FDA for Supplemental Biologics License Applications for Keytruda Six-Week Dosing Schedule. Feb 20, 2020 257
Advaxis and Personalis Ink Research Agreement to Deploy ImmunoID NeXT Platform in the ADXS-503 Clinical Programme. Feb 14, 2020 486
Genprex to Focus Its Clinical Efforts on Oncoprex in Combination Therapy with Osimertinib for Non-Small Cell Lung Cancer. Feb 11, 2020 684
Genprex prioritizing Oncoprex development in combo with AstraZeneca's Tagrisso to treat non-small cell lung cancer. Feb 6, 2020 667
Scancell receives US regulatory green light. Feb 4, 2020 290
Scancell Gets US FDA Approval For SCIB1 Drug Application. Feb 3, 2020 159
Outcomes and prognosticators of stage 4 renal cell carcinoma with pathological T4 primary lesion using a large, Canadian, multi-institutional database. Oake, Justin D.; Patel, Premal; Lavallee, Luke T.; Lattouf, Jean-Baptiste; Saarela, Olli; Klotz, Lau Feb 1, 2020 4689
US Food and Drug Administration (FDA) grants priority review of belantamab mafodotin for patients with relapsed or refractory multiple myeloma. Jan 21, 2020 1120
Immunotherapy Drugs Market Size Projection, Growth Statistics, Future Trends, Regional insights By 2023. Jan 15, 2020 856
Paraneoplastic leukemoid reaction associated with poor prognosis in oral squamous cell carcinoma: A case report and literature review. Hsieh, Li-Tsun; Lin, Chien-Liang; Chang, Yu-Kang; Ho, Sheng-Yow Jan 1, 2020 1599
Successful Treatment for Hypercalcemia due to Cosecretion of Parathyroid Hormone-Related Protein and 1, 25-Dihydroxyvitamin [D.sub.3] in Non-Small-Cell Lung Cancer: A Case Report and Literature Review. Ogawa, Takunori; Miyata, Jun; Fukunaga, Koichi; Kawana, Akihiko; Inoue, Takashi Jan 1, 2020 2339
Rapid Affinity Maturation of Novel Anti-PD-L1 Antibodies by a Fast Drop of the Antigen Concentration and FACS Selection of Yeast Libraries. Cembrola, Biancamaria; Ruzza, Valentino; Troise, Fulvia; Esposito, Maria Luisa; Sasso, Emanuele; Caf Jan 1, 2020 15860
Clinical Features of Liver Injury Induced by Immune Checkpoint Inhibitors in Japanese Patients. Imoto, Koji; Kohjima, Motoyuki; Hioki, Tomonobu; Kurashige, Tomoyuki; Kurokawa, Miho; Tashiro, Shige Dec 31, 2019 7227
Combination with Stereotactic Body Radiotherapy Offers a Promising Strategy to Overcome Resistance to Immunotherapy in Advanced Renal Cell Cancer. Sun, Xiaowen; Gan, Lu; Na, Aru; Ge, Lingling; Chen, Baoqing; Liu, Jiaming Dec 31, 2019 9231
Innovation in Oncology Drug Development. Huber, Matthew; Huber, Brian Dec 31, 2019 12396
Safety and Efficacy in Relapsed or Refractory Classic Hodgkin's Lymphoma Treated with PD-1 Inhibitors: A Meta-Analysis of 9 Prospective Clinical Trials. Zhang, Xueyan; Chen, Li; Zhao, Yawei; Yin, Huiru; Ma, He; He, Miao Dec 31, 2019 9556
Dramatic Response to First Line Single Agent Pembrolizumab in Anaplastic Thyroid Carcinoma. Spalart, Valerie; Legius, Barbara; Segers, Kurt; Coolen, Johan; Maes, Brigitte; Decoster, Lynn Dec 31, 2019 1790
An Exceptional Responder to Nivolumab in Metastatic Non-Small-Cell Lung Cancer: A Case Report and Literature Review of Long-Term Survivors. Baseri, Babak; Samra, Bachar; Tam, Eric; Chiu, Edwin; Leaf, Andrea Dec 31, 2019 4860
Safe Transition to Pembrolizumab following Ipilimumab-Induced Guillain-Barre Syndrome: A Case Report and Review of the Literature. Gravbrot, Nicholas; Scherer, Katalin; Sundararajan, Srinath Dec 31, 2019 3220
Pivotal DREAMM-2 study demonstrated a clinically meaningful overall response rate with belantamab mafodotin (GSK2857916) for patients with relapsed/refractory multiple myeloma. Dec 17, 2019 1732
Global Soft Tissue Sarcoma (STS) Market Insights, Epidemiology, and Market Forecast 2019-2028. Dec 16, 2019 859
Global Kidney Cancer Drugs Market Report 2020: Focus on Nexavar, Sutent, Afinitor, Votrient, Avastin, Inlyta, Torisel, Proleukin. Report Dec 11, 2019 989
ASH: AlloHSCT Feasible After PD-1, PD-L1 mAb in Hodgkin Lymphoma; Outcomes good for those treated with a PD-1 or PD-L1 inhibitor before undergoing allogeneic HSCT. Dec 10, 2019 258
Eisai Satisfies All-Case Surveillance Condition for Approval of Anti-Cancer Agent Lenvima in Treatment of Thyroid Cancer. Dec 9, 2019 1144
Advaxis Submits IND Application to US FDA for ADXS-HOT Drug Candidate for Prostate Cancer. Dec 6, 2019 363
Global Cancer Immunotherapy Market: $100+ Billion Analysis & Forecast 2020-2023. Dec 4, 2019 1496
Seattle Genetics, Astellas Forge Clinical Trial Collaboration with US Merck to Evaluate Enfortumab. Dec 3, 2019 456
Eisai: Additional Indication for Lenvima (Lenvatinib) for Differentiated Thyroid Cancer Accepted in China. Dec 2, 2019 1321
TLR9 agonist may overcome resistance to anti-PD-1 melanoma therapy. Smith, Jennifer Dec 1, 2019 422
What the Oncologist Needs From the Pathologist for Immune Therapies. Bernicker, Eric H. Dec 1, 2019 3001
Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer. Carbone, Carmine; Piro, Geny; Noia, Vincenzo Di; D'Argento, Ettore; Vita, Emanuele; Ferrara, Miriam Nov 30, 2019 6998
Beyond T Cells: Understanding the Role of PD-1/PD-L1 in Tumor-Associated Macrophages. Lu, Di; Ni, Zhen; Liu, Xiguang; Feng, Siyang; Dong, Xiaoying; Shi, Xiaoshun; Zhai, Jianxue; Mai, Shi Nov 30, 2019 5370
The Role of Immunotherapy in Extensive Stage Small-Cell Lung Cancer: A Review of the Literature. Tsiouprou, Ioanna; Zaharias, Athanasios; Spyratos, Dionisios Nov 30, 2019 5174
Implications for Tumor Microenvironment and Epithelial Crosstalk in the Management of Gastrointestinal Cancers. Ge, Yang; Westphalen, C. Benedikt; Ma, Wen Wee; Vega, Kenneth J.; Weygant, Nathaniel Disease/Disorder overview Nov 30, 2019 9178
Monoclonal Antibody Therapies in Multiple Myeloma: A Challenge to Develop Novel Targets. Nishida, Hiroko; Yamada, Taketo Nov 30, 2019 7486
Cryosurgery, Intralesional Methotrexate and Imiquimod for Keratoacanthoma: Tuning the Combination. Gaitanis, Georgios; Bassukas, Ioannis D. Nov 30, 2019 2839
Vitiligo Associated with Melanoma in a Malagasy Woman. Ranaivo, I.M.; Sendrasoa, F.A.; Andrianarison, M.; Razakanaivo, M.; Ramarozatovo, L.S.; Rafaramino, Nov 30, 2019 1762
Aseptic Meningitis as an Immune-Related Adverse Event after Pembrolizumab. Lima, Gian; Kahn, Adriana; Sama, Shashank; Savage, Jacqueline Nov 30, 2019 1126
Immune Checkpoint Inhibitor Induced Diabetes Mellitus Treated with Insulin and Metformin: Evolution of Diabetes Management in the Era of Immunotherapy. Alrifai, Taha; Ali, Faisal Shaukat; Saleem, Sameer; Ruiz, Diana Carolina Miranda; Rifai, Dana; Youna Nov 30, 2019 1964
Tiptoeing on Metastatic Adenocarcinoma of the Lung. Kochar, Arupreet; Winters, Harrison D.; Zhang, Li; Zhang, Bin; Thakur, Kamia; Essrani, Rajesh Nov 30, 2019 1119
Men with prostate cancer can live longer on immunotherapy, study finds. ANI Nov 30, 2019 558
Prostate cancer can rely on immunotherapy for treatment: Study. ANI Nov 28, 2019 539

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |